Skip to main content

Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Publication ,  Other
Lampert, EJ; Zimmer, A; Padget, M; Cimino-Mathews, A; Nair, JR; Liu, Y; Swisher, EM; Hodge, JW; Nixon, AB; Nichols, E; Bagheri, MH; Levy, E ...
March 31, 2023

<p>Supplementary methods, tables, figures 1-5 with corresponding figure legends, and references</p>

Duke Scholars

DOI

Publication Date

March 31, 2023
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., … Lee, J.-M. (2023). Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. https://doi.org/10.1158/1078-0432.22479107
Lampert, Erika J., Alexandra Zimmer, Michelle Padget, Ashley Cimino-Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, et al. “Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22479107.
Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee J-M. Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. 2023.

DOI

Publication Date

March 31, 2023